Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
EVRAZ plc was notified on 29 March 2019 by Mr. Alexander Abramov, a director of EVRAZ plc, that he placed an order to purchase EVRAZ 5.25% notes due in 2024 for total principal amount of $50m. As a result of this transaction, Mr. Alexander Abramov's holding will increase to $50m EVRAZ 5.25% notes due in 2024. Settlement of the transaction is expected to be completed on 2 April 2019.
The notification below, made in accordance with the requirements of the Article 19 of EU Market Abuse Regulation, provides further detail.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||||||||||||||||||
|
a) |
Name |
Alexander Abramov |
|||||||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||||||
|
a) |
Position/status |
Director, Non-Executive Chairman of the Board |
|||||||||||||||||||||||||
|
b) |
Initial notification/ Amendment |
Initial notification |
|||||||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||||||
|
a) |
Name |
EVRAZ plc |
|||||||||||||||||||||||||
|
b) |
LEI |
5493005B7DAN39RXLK23 |
|||||||||||||||||||||||||
|
4 |
Details of the transaction(s): |
||||||||||||||||||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
5.25% notes due in 2024 XS1843443273 |
|||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Purchase of notes |
|||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||||||||||||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
||||||||||||||||||||||||||
|
e) |
Date/time of the transactions |
||||||||||||||||||||||||||
|
f) |
Place of the transaction |
Primary offering |
|||||||||||||||||||||||||
EVRAZ plc was notified on 29 March 2019 by Mr. Alexander Frolov, a director of EVRAZ plc, that he placed an order to purchase EVRAZ 5.25% notes due in 2024 for total principal amount of $20m. As a result of this transaction, Mr. Alexander Frolov's holding will increase to $20m EVRAZ 5.25% notes due in 2024. Settlement of the transaction is expected to be completed on 2 April 2019.
The notification below, made in accordance with the requirements of the Article 19 of EU Market Abuse Regulation, provides further detail.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||||||||||||||||||
|
a) |
Name |
Alexander Frolov |
|||||||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||||||
|
a) |
Position/status |
Director, CEO |
|||||||||||||||||||||||||
|
b) |
Initial notification/ Amendment |
Initial notification |
|||||||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||||||
|
a) |
Name |
EVRAZ plc |
|||||||||||||||||||||||||
|
b) |
LEI |
5493005B7DAN39RXLK23 |
|||||||||||||||||||||||||
|
4 |
Details of the transaction(s): |
||||||||||||||||||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
5.25% notes due in 2024 XS1843443273 |
|||||||||||||||||||||||||
|
b) |
Nature of the transaction |
Purchase of notes |
|||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||||||||||||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
||||||||||||||||||||||||||
|
e) |
Date/time of the transactions |
||||||||||||||||||||||||||
|
f) |
Place of the transaction |
Primary offering |
|||||||||||||||||||||||||
EVRAZ Investor Relations
+7 495 232 1370
29 March 2019
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.